Exhibit 99.1
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare
Investor, to its Board of Directors
WATERTOWN, Massachusetts, March 4, 2024 Acrivon Therapeutics, Inc.
(Acrivon or Acrivon Therapeutics) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific
medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors.
Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation
precision medicine platform, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. Santhosh has not only served on numerous boards providing his expertise on the business side as a
successful private and public healthcare investor, but earlier in his career he was also a drug developer, so we are delighted to have him join our board.
Dr. Palani is a former investment partner and a current advisory partner at PFM Health Sciences. At PFM, Dr. Palani led public and private
biotechnology investments, and served on the board of companies in the cell therapy and gene editing fields. Prior to joining PFM in 2020, Dr. Palani was a principal at New Enterprise Associates (NEA) where he invested in early-stage private
biotechnology companies and served on the boards of companies in the radiopharmaceuticals, cell therapy, targeted oncology, and gene editing fields. From 2016 to 2018, Dr. Palani was the vice president of equity research at Cowen and Company,
where he covered small- to mid-cap biotechnology stocks across numerous therapeutic areas. Prior to Cowen, Dr. Palani was in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals.
Dr. Palani has a Ph.D. in bioengineering from the University of Pennsylvania and completed his postdoctoral work in biochemistry and molecular biophysics at Columbia University. He also holds an M.S. in chemical engineering from Texas A&M
University and a B.S. in chemical engineering from the University of Madras. Dr. Palani is a CFA® Charterholder.
Dr. Palani added, Acrivon is an entirely science-based company and its AP3 platform is a ground-breaking approach which is broadly applicable
across drug discovery and development with significant unrealized potential not only in oncology but also in other areas including autoimmune and metabolic disorders, as dysregulated signaling ultimately underlies all diseases. The company
currently is focused on oncology with a highly differentiated profile in this space. I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the companys current pipeline and
beyond.
About Acrivon Therapeutics
Acrivon
is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivons proprietary proteomics-based patient
responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure